Table 2.

Baseline patient characteristics (N = 61)

Median age, y (range)46 (32-72)
Karnofsky performance status (%)
    10046 (75.4)
    906 (9.8)
    805 (8.2)
    704 (6.6)
Histology (%)
    Ductal breast59 (96.7)
    Lobular breast1 (1.6)
    Tubular/lobular breast1 (1.6)
Menopausal status (%)
    Premenopausal19 (31.1)
    Perimenopausal19 (31.1)
    Postmenopausal23 (37.7)
Estrogen/progesterone receptor status (%)*
    +/+19 (31.1)
    +/−8 (13.1)
    −/+2 (3.3)
    −/−27 (44.3)
    U/U2 (3.3)
TNM staging (%)
    T4 N0 M03 (4.9)
    T4 N1 M042 (68.9)
    T4 N1 M11 (1.6)
    T4 N2 M09 (14.8)
    T4 N2 M16 (9.8)
  • * Estrogen receptor status was not done for three patients.

  • U/U, estrogen receptor/progesterone receptor status could not be determined.

  • Sites of metastases included supraclavicular lymph nodes, liver, pleura, and bone.